Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published Announced on 10 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
There was no significant deviation from the previous forecast in net sales or operating income, while ordinary income fell below the forecast due to equity-method investment losses and other items. Net income attributable to owners of the parent and standalone net income fell below the forecast due to the recognition of extraordinary losses on a consolidated and standalone basis, among other factors.
On a consolidated basis, an equity-method investment loss of ¥4.2 billion was recognized as a non-operating expense, and extraordinary losses of ¥18.9 billion were recognized. These comprised an impairment loss of ¥10.6 billion on MGC Pure Chemicals Taiwan, an impairment loss of ¥5.3 billion in the polycarbonate business, an impairment loss of ¥1.9 billion on MGC Specialty Chemicals Netherlands, and a ¥1.0 billion loss associated with the cancellation of construction work. On a standalone basis, the Company recognized a ¥3.4 billion valuation loss on shares of a Taiwanese subsidiary, a ¥1.9 billion provision for doubtful accounts, a ¥1.7 billion provision for losses on the business of an affiliate, a ¥5.3 billion impairment loss in the polycarbonate business, a ¥5.1 billion provision for doubtful accounts and a ¥0.7 billion valuation loss on shares of 日本トリニダードメタノール, a ¥0.4 billion provision for losses on guarantees of debt for Caribbean Gas Chemical, and a ¥3.1 billion valuation loss on shares of a Dutch subsidiary.
| Item | Details |
|---|---|
| Net Sales | Consolidated 730,000 / Individual 410,000 → Consolidated 738,243 / Individual 407,509（Consolidated 1.1 / Individual -0.6） |
| Operating profit | Consolidated 47,000 / Individual 19,000 → Consolidated 45,293 / Individual 16,115（Consolidated -3.6 / Individual -15.2） |
| Ordinary income | Consolidated 55,000 / Individual 38,000 → Consolidated 51,947 / Individual 35,834（Consolidated -5.6 / Individual -5.7） |
| Profit attributable to owners of the parent | Consolidated -18,000 / Individual -25,000 → Consolidated -40,318 / Individual -47,080 |
| Net income per share | Consolidated -92.43 / Individual -128.38 → Consolidated -207.04 / Individual -241.77 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | Announced on 10 February 2026 |
| Previous-period results | Consolidated: net sales of ¥773,591 million, operating income of ¥50,851 million, ordinary income of ¥60,316 million, net income attributable to owners of the parent of ¥45,544 million, and net income per share of ¥228.93. Standalone: net sales of ¥432,839 million, operating income of ¥22,581 million, ordinary income of ¥36,575 million, net income of ¥34,894 million, and net income per share of ¥175.40. |
| Reason for the revision | There was no significant deviation from the previous forecast in net sales or operating income, while ordinary income fell below the forecast due to equity-method investment losses and other items. Net income attributable to owners of the parent and standalone net income fell below the forecast due to the recognition of extraordinary losses on a consolidated and standalone basis, among other factors. |
| Details and amount of extraordinary loss | On a consolidated basis, an equity-method investment loss of ¥4.2 billion was recognized as a non-operating expense, and extraordinary losses of ¥18.9 billion were recognized. These comprised an impairment loss of ¥10.6 billion on MGC Pure Chemicals Taiwan, an impairment loss of ¥5.3 billion in the polycarbonate business, an impairment loss of ¥1.9 billion on MGC Specialty Chemicals Netherlands, and a ¥1.0 billion loss associated with the cancellation of construction work. On a standalone basis, the Company recognized a ¥3.4 billion valuation loss on shares of a Taiwanese subsidiary, a ¥1.9 billion provision for doubtful accounts, a ¥1.7 billion provision for losses on the business of an affiliate, a ¥5.3 billion impairment loss in the polycarbonate business, a ¥5.1 billion provision for doubtful accounts and a ¥0.7 billion valuation loss on shares of 日本トリニダードメタノール, a ¥0.4 billion provision for losses on guarantees of debt for Caribbean Gas Chemical, and a ¥3.1 billion valuation loss on shares of a Dutch subsidiary. |
| Consolidated / non-consolidated | Consolidated / non-consolidated (standalone) |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company attributed the shortfall in ordinary income to equity-method investment losses and other items, and the shortfalls in net income attributable to owners of the parent and standalone net income to extraordinary losses, including impairment losses. The Company stated that there was no significant deviation from the previous forecast in net sales or operating income.